TCIM
CBAY

TIAA CREF Investment Management’s Cymabay Therapeutics CBAY Stock Holding History

TIAA CREF Investment Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$3.03M Buy
228,235
+62,275
+38% +$662K ﹤0.01% 1759
2018
Q4 		$1.31M Sell
165,960
-536
-0.3% -$5.1K ﹤0.01% 2181
2018
Q3 		$1.84M Sell
166,496
-45,390
-21% -$564K ﹤0.01% 2161
2018
Q2 		$2.84M Buy
+211,886
New +$2.65M ﹤0.01% 1982

Other funds holding CBAY

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

TIAA CREF Investment Management's CBAY Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Cymabay Therapeutics (CBAY) stake by 38% in Q1 2019, buying an estimated $662K and bringing the position to 228,235 shares worth $3.03M. The position accounts for ﹤0.01% of the portfolio, ranked #1759.

TIAA CREF Investment Management first reported a position in CBAY in Q2 2018 and has held it in 4 quarters since. 143 funds tracked by Wall St. Rank hold CBAY as of Q1 2019.

  • TIAA CREF Investment Management held 228,235 shares of Cymabay Therapeutics worth $3.03M as of Q1 2019.
  • TIAA CREF Investment Management bought 62,275 Cymabay Therapeutics shares in Q1 2019, an estimated $662K.
  • Cymabay Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #1759 holding.
  • TIAA CREF Investment Management first reported a position in Cymabay Therapeutics in Q2 2018 and has held it in 4 quarters since.
  • 143 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.